Patents by Inventor Jason C. Wagner

Jason C. Wagner has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Thienopyrimidine inhibitors of atypical protein kinase C
    Patent number: 10954251
    Abstract: The present application provides a compound of formula (I) or a salt thereof, wherein R1, R2, R3, R4, R5, R6, A, G, M, Q and X are as defined herein. A compound of formula (I) and its salts have a PKC inhibitory activity, and may be used to treat proliferative disorders.
    Type: Grant
    Filed: December 6, 2018
    Date of Patent: March 23, 2021
    Assignee: Cancer Research Technology Limited
    Inventors: Bruce D. Dorsey, Keith S. Learn, Emma L. Morris, Gregory R. Ott, Jonathan R. A. Roffey, Christelle N. Soudy, Jason C. Wagner
  • THIENOPYRIMIDINE INHIBITORS OF ATYPICAL PROTEIN KINASE C
    Publication number: 20190106433
    Abstract: The present application provides a compound of formula (I) or a salt thereof, wherein R1, R2, R3, R4, R5, R6, A, G, M, Q and X are as defined herein. A compound of formula (I) and its salts have a PKC inhibitory activity, and may be used to treat proliferative disorders.
    Type: Application
    Filed: December 6, 2018
    Publication date: April 11, 2019
    Inventors: Bruce D. DORSEY, Keith S. LEARN, Emma L. MORRIS, Gregory R. OTT, Jonathan R.A. ROFFEY, Christelle N. SOUDY, Jason C. WAGNER
  • Thienopyrimidine inhibitors of atypical protein kinase C
    Patent number: 10183950
    Abstract: The present application provides a compound of formula (I) or a salt thereof, wherein R1, R2, R3, R4, R5, R6, A, G, M, Q and X are as defined herein. A compound of formula (I) and its salts have aPKC inhibitory activity, and may be used to treat proliferative disorders.
    Type: Grant
    Filed: January 26, 2017
    Date of Patent: January 22, 2019
    Assignee: Cancer Research Technology Limited
    Inventors: Bruce D. Dorsey, Keith S. Learn, Emma L. Morris, Gregory R. Ott, Jonathan R. A. Roffey, Christelle N. Soudy, Jason C. Wagner
  • THIENOPYRIMIDINE INHIBITORS OF ATYPICAL PROTEIN KINASE C
    Publication number: 20170158706
    Abstract: The present application provides a compound of formula (I) or a salt thereof, wherein R1, R2, R3, R4, R5, R6, A, G, M, Q and X are as defined herein. A compound of formula (I) and its salts have aPKC inhibitory activity, and may be used to treat proliferative disorders.
    Type: Application
    Filed: January 26, 2017
    Publication date: June 8, 2017
    Applicant: Cancer Research Technology Limited
    Inventors: Bruce D. Dorsey, Keith S. Learn, Emma L. Morris, Gregory R. Ott, Jonathan R.A. Roffey, Christelle N. Soudy, Jason C. Wagner
  • Thienopyrimidine inhibitors of atypical protein kinase C
    Patent number: 9604994
    Abstract: The present application provides a compound of formula (I) or a salt thereof, wherein R1, R2, R3, R4, R5, R6, A, G, M, Q and X are as defined herein. A compound of formula (I) and its salts have aPKC inhibitory activity, and may be used to treat proliferative disorders.
    Type: Grant
    Filed: May 22, 2014
    Date of Patent: March 28, 2017
    Assignee: Cancer Research Technology Limited
    Inventors: Bruce D Dorsey, Keith S. Learn, Emma L. Morris, Gregory R Ott, Jonathan R. A. Roffey, Christelle N. Soudy, Jason C. Wagner
  • Imidazo[4,5-b]pyridine derivatives as ALK and JAK modulators for the treatment of proliferative disorders
    Patent number: 9238656
    Abstract: This application relates to compounds of the Formula I as defined herein, and/or salts thereof. This application further relates to compositions and methods of using these compounds and/or salts thereof. The compounds of Formula I are useful as ALK and JAK modulators for the treatment of proliferative disorders.
    Type: Grant
    Filed: July 30, 2014
    Date of Patent: January 19, 2016
    Assignee: Cephalon, Inc.
    Inventors: Henry J. Breslin, Matthew A. Curry, Diane E. Gingrich, Keith S. Learn, Gregory R. Ott, Jason C. Wagner
  • Imidazo[4,5-b]pyridine Derivatives as ALK and JAK Modulators for the Treatment of Proliferative Disorders
    Publication number: 20140350011
    Abstract: This application relates to compounds of the Formula I as defined herein, and/or salts thereof. This application further relates to compositions and methods of using these compounds and/or salts thereof. The compounds of Formula I are useful as ALK and JAK modulators for the treatment of proliferative disorders.
    Type: Application
    Filed: July 30, 2014
    Publication date: November 27, 2014
    Inventors: Henry J. Breslin, Matthew A. Curry, Diane E. Gingrich, Keith S. Learn, Gregory R. Ott, Jason C. Wagner
  • Thienopyrimidine Inhibitors of Atypical Protein Kinase C
    Publication number: 20140323435
    Abstract: The present application provides a compound of formula (I) or a salt thereof, wherein R1, R2, R3, R4, R5, R6, A, G, M, Q and X are as defined herein. A compound of formula (I) and its salts have aPKC inhibitory activity, and may be used to treat proliferative disorders.
    Type: Application
    Filed: May 22, 2014
    Publication date: October 30, 2014
    Applicants: Cancer Research Technology Limited, Cephalon, Inc.
    Inventors: Bruce D. Dorsey, Keith S. Learn, Emma L. Morris, Gregory R. Ott, Jonathan R.A. Roffey, Christelle N. Soudy, Jason C. Wagner
  • Substituted bicyclic pyrimidines
    Patent number: 8354414
    Abstract: The present invention is related to chemical compositions, processes for the preparation thereof and uses of the composition. Particularly, the present invention relates to compositions that include substituted heterobicyclic pyrimidines of Formula (I): wherein R1, R2, R3, R4, R5, X, W, and ring A are as defined herein; pharmaceutical compositions of substituted heterobicyclic pyrimidines of Formula (I); and their use in the treatment of chronic neurodegenerative diseases, neurotraumatic diseases, depression and/or diabetes. More particularly, the present invention relates to substituted pyrazolopyrimidines of Formula (I).
    Type: Grant
    Filed: November 4, 2010
    Date of Patent: January 15, 2013
    Assignee: Cephalon, Inc
    Inventors: Edward R. Bacon, Thomas Bailey, Nadine C. Becknell, Diane E. Gingrich, Greg A. Hostetler, Robert L. Hudkins, Keith S. Learn, Jason C. Wagner
  • SUBSTITUTED BICYCLIC PYRIMIDINES
    Publication number: 20110053920
    Abstract: The present invention is related to chemical compositions, processes for the preparation thereof and uses of the composition. Particularly, the present invention relates to compositions that include substituted heterobicyclic pyrimidines of Formula (I): wherein R1, R2, R3, R4, R5, X, W, and ring A are as defined herein; pharmaceutical compositions of substituted heterobicyclic pyrimidines of Formula (I); and their use in the treatment of chronic neurodegenerative diseases, neurotraumatic diseases, depression and/or diabetes. More particularly, the present invention relates to substituted pyrazolopyrimidines of Formula (I).
    Type: Application
    Filed: November 4, 2010
    Publication date: March 3, 2011
    Applicant: CEPHALON, INC.
    Inventors: Edward R. Bacon, Thomas Bailey, Nadine C. Becknell, Diane E. Gingrich, Greg Hostetler, Robert L. Hudkins, Keith S. Learn, Jason C. Wagner
  • Substituted pyrazolo[3,4-d]pyrimidines
    Patent number: 7851468
    Abstract: The present invention is related to chemical compositions, processes for the preparation thereof and uses of the composition. Particularly, the present invention relates to compositions that include substituted heterobicyclic pyrimidines of Formula (I): wherein R1, R2, R3, R4, R5, X, W, and ring A are as defined herein; pharmaceutical compositions of substituted heterobicyclic pyrimidines of Formula (I); and their use in the treatment of chronic neurodegenerative diseases, neurotraumatic diseases, depression and/or diabetes. More particularly, the present invention relates to substituted pyrazolopyrimidines of Formula (I).
    Type: Grant
    Filed: May 14, 2007
    Date of Patent: December 14, 2010
    Assignee: Cephalon, Inc.
    Inventors: Edward R. Bacon, Thomas Bailey, Nadine C. Becknell, Diane E. Gingrich, Greg Hostetler, Robert L. Hudkins, Keith S. Learn, Jason C. Wagner
  • FUSED BICYCLIC DERIVATIVES OF 2,4-DIAMINOPYRIMIDINE AS ALK AND c-MET INHIBITORS
    Publication number: 20090221555
    Abstract: The present invention provides a compound of formula I or II or a pharmaceutically acceptable salt form thereof, wherein R1, R2, R3, R4, R5, A1, A2, A3, A4, and A5, are as defined herein. The compounds of formula I or II have ALK and/or c-Met inhibitory activity, and may be used to treat proliferative disorders.
    Type: Application
    Filed: October 23, 2007
    Publication date: September 3, 2009
    Applicants: Cephalon, Inc., Pharmacopeia Drug Discovery, Inc.
    Inventors: Gulzar Ahmed, Adolph Bohnstedt, Henry Joseph Breslin, Jason Burke, Matthew A. Curry, James L. Diebold, Bruce Dorsey, Benjamin J. Dugan, Daming Feng, Diane E. Gingrich, Tao Guo, Koc-Kan Ho, Keith S. Learn, Joseph G. Lisko, Rong-qiang Liu, Eugen Mesaros, Karen Milkiewicz, Gregory R. Ott, Jonathan Parrish, Jay P. Theroff, Tho V. Thieu, Rabindranath Tripathy, Theodore L. Underiner, Jason C. Wagner, Linda Weinberg, Gregory J. Wells, Ming You, Craig A. Zificsak